SynthesisBritish journal of haematology2026
Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.
Synthesis in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Contemporary global burden of sickle cell anaemia under-5 and under-20: A systematic review and meta-analysis.British journal of haematology · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sickle cell disease (SCD), a prevalent inherited non-communicable disease, remains a neglected public health priority, especially children and adolescents in many low- and middle-income countries. The global burden of SCD in youth remains under-characterized given fragmented data and disparities in diagnostics. This study aims to conduct a systematic review and meta-analysis quantifying the global prevalence and cause-specific mortality of SCD in individuals aged under-5 and under-20. A search was conducted to identify studies reporting SCD prevalence or mortality published between 2017 and 2023. Eligible studies were assessed for quality and random-effects meta-analyses generated pooled estimates, stratified by age group, study design and United Nations country group classification. Fifty-seven studies were included, encompassing data from over 3.6 million individuals and 56 593 recorded deaths. Among children under-5, the prevalence was 0.008 (95% confidence interval [CI]: 0.004-0.016). The global under-20 population-based prevalence of SCD was 0.009 (95% CI: 0.005-0.017). The global under-20 cause-specific mortality proportion was 0.029 (95% CI: 0.001-0.621), with under-5 and 5-19 years of age mortality proportions estimated at 0.021 and 0.017, respectively. This first global synthesis of under-5s and under-20s demonstrates substantial paediatric burden but is constrained by extreme heterogeneity, wide uncertainty and incomplete geographic coverage, underscoring the urgency for improved screening, surveillance and cause-of-death attribution to support accurate global burden estimation of SCD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.